Insider Transactions in Q1 2022 at Eli Lilly & CO (LLY)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
2,500
-0.0%
|
$730,000
$292.03 P/Share
|
|
Mar 29
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
4,341
-0.0%
|
$1,267,572
$292.68 P/Share
|
|
Mar 28
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
7,538
-0.01%
|
$2,201,096
$292.15 P/Share
|
|
Mar 21
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
35,245
-0.02%
|
$10,291,540
$292.74 P/Share
|
|
Mar 21
2022
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
34
+0.05%
|
$9,826
$289.64 P/Share
|
|
Mar 21
2022
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
34
+4.09%
|
$9,826
$289.64 P/Share
|
|
Mar 21
2022
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
39
+0.08%
|
$11,271
$289.64 P/Share
|
|
Mar 21
2022
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
43
+0.31%
|
$12,427
$289.64 P/Share
|
|
Mar 21
2022
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
33
+2.74%
|
$9,537
$289.64 P/Share
|
|
Mar 18
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
210,000
-0.07%
|
$60,480,000
$288.4 P/Share
|
|
Mar 17
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
220,000
-0.07%
|
$62,260,000
$283.95 P/Share
|
|
Mar 17
2022
|
Patrik Jonsson EVP&Pres, LLY Dia&Obe, LLY USA |
SELL
Open market or private sale
|
Direct |
673
-2.1%
|
$186,421
$277.2 P/Share
|
|
Mar 15
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
220,075
-0.03%
|
$60,080,475
$273.77 P/Share
|
|
Mar 14
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
173,085
-0.08%
|
$46,559,865
$269.73 P/Share
|
|
Mar 11
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
21,840
-0.02%
|
$5,874,960
$269.05 P/Share
|
|
Mar 10
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
184,982
-0.09%
|
$49,205,212
$266.79 P/Share
|
|
Mar 09
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
20,018
-0.01%
|
$5,324,788
$266.94 P/Share
|
|
Mar 04
2022
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
210,000
-0.05%
|
$55,020,000
$262.14 P/Share
|
|
Mar 01
2022
|
Marschall S Runge Director |
BUY
Open market or private purchase
|
Direct |
202
+1.29%
|
$49,692
$246.78 P/Share
|
|
Mar 01
2022
|
Patrik Jonsson EVP&Pres, LLY Dia&Obe, LLY USA |
SELL
Open market or private sale
|
Direct |
675
-2.06%
|
$166,725
$247.56 P/Share
|
|
Mar 01
2022
|
Anat Hakim EVP, GC & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
3,500
-28.31%
|
$871,500
$249.95 P/Share
|
|
Mar 01
2022
|
Anat Hakim EVP, GC & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,929
+39.07%
|
-
|
|
Feb 25
2022
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Open market or private sale
|
Direct |
1,660
-18.58%
|
$403,380
$243.84 P/Share
|
|
Feb 22
2022
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
41
+0.06%
|
$9,799
$239.13 P/Share
|
|
Feb 22
2022
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
53
+0.39%
|
$12,667
$239.13 P/Share
|
|
Feb 22
2022
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
40
+3.41%
|
$9,560
$239.13 P/Share
|
|
Feb 22
2022
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
41
+5.11%
|
$9,799
$239.13 P/Share
|
|
Feb 22
2022
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
47
+0.09%
|
$11,233
$239.13 P/Share
|
|
Feb 16
2022
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
2,186
-21.53%
|
$531,198
$243.84 P/Share
|
|
Feb 16
2022
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
5,461
+34.98%
|
-
|
|
Feb 16
2022
|
Ilya Yuffa EVP & President, LLY Int'l |
SELL
Open market or private sale
|
Direct |
1,000
-7.92%
|
$242,000
$242.58 P/Share
|
|
Feb 15
2022
|
Ilya Yuffa EVP & President, LLY Int'l |
SELL
Open market or private sale
|
Direct |
1,000
-7.34%
|
$237,000
$237.45 P/Share
|
|
Feb 09
2022
|
Anat Ashkenazi EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,752
+15.47%
|
$1,397,736
$243.27 P/Share
|
|
Feb 09
2022
|
Stephen F Fry SVP, HR & Diversity |
BUY
Grant, award, or other acquisition
|
Direct |
12,339
+7.48%
|
$2,998,377
$243.27 P/Share
|
|
Feb 09
2022
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,435
+20.87%
|
$1,320,705
$243.27 P/Share
|
|
Feb 09
2022
|
Patrik Jonsson EVP&Pres, LLY Dia&Obe, LLY USA |
BUY
Grant, award, or other acquisition
|
Direct |
2,036
+5.86%
|
$494,748
$243.27 P/Share
|
|
Feb 09
2022
|
Michael B Mason EVP & Pres., Lilly Diabetes |
BUY
Grant, award, or other acquisition
|
Direct |
2,612
+8.67%
|
$634,716
$243.27 P/Share
|
|
Feb 09
2022
|
Johna Norton EVP, Global Quality |
BUY
Grant, award, or other acquisition
|
Direct |
3,294
+9.82%
|
$800,442
$243.27 P/Share
|
|
Feb 09
2022
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
BUY
Grant, award, or other acquisition
|
Direct |
5,309
+16.83%
|
$1,290,087
$243.27 P/Share
|
|
Feb 09
2022
|
David A Ricks President, Chair, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
68,004
+12.69%
|
$16,524,972
$243.27 P/Share
|
|
Feb 09
2022
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Grant, award, or other acquisition
|
Direct |
22,581
+22.33%
|
$5,487,183
$243.27 P/Share
|
|
Feb 09
2022
|
Alonzo Weems EVP, ERM & CECO |
BUY
Grant, award, or other acquisition
|
Direct |
3,731
+29.79%
|
$906,633
$243.27 P/Share
|
|
Feb 09
2022
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Grant, award, or other acquisition
|
Direct |
11,348
+18.39%
|
$2,757,564
$243.27 P/Share
|
|
Feb 09
2022
|
Ilya Yuffa EVP & President, LLY Int'l |
BUY
Grant, award, or other acquisition
|
Direct |
3,275
+19.38%
|
$795,825
$243.27 P/Share
|
|
Feb 09
2022
|
Donald A Zakrowski SVP, Finance, & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
2,947
+24.8%
|
$716,121
$243.27 P/Share
|
|
Feb 01
2022
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
25,170
-5.92%
|
$6,166,650
$245.39 P/Share
|
|
Feb 01
2022
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
56,205
+11.68%
|
-
|
|
Feb 01
2022
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
SELL
Payment of exercise price or tax liability
|
Direct |
8,437
-13.1%
|
$2,067,065
$245.39 P/Share
|
|
Feb 01
2022
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Exercise of conversion of derivative security
|
Direct |
18,735
+22.53%
|
-
|
|
Feb 01
2022
|
Stephen F Fry SVP, HR & Diversity |
SELL
Payment of exercise price or tax liability
|
Direct |
4,554
-3.14%
|
$1,115,730
$245.39 P/Share
|